Using analytics and bioassays to de-risk your mRNA LNP drug development programme
The launch of the mRNA Pfizer and Moderna vaccines changed therapeutics overnight, but the technologies and processes involved in mRNA-based applications are still emerging. With no free-to-use template to scale sequences quickly, having a deep understanding of LNP analytics and bioassays becomes crucial to accelerate commercialisation.
